RNTX

NASDAQ 已收盘

Rein Therapeutics

0.34 USD
▼-0.03-8.38%
盘后 0.39 +15.76%
2026-11-20
市值
$29.06M
市盈率
—
EPS
-0.93
股息率
—
52 周区间
0.28 – 2.10
成交量
668.75K
Beta
1.44
目标价
6.00
52W 低 0.2852W 高 2.10
价格走势

公司简介

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company’s lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company’s pipeline also includes preclinical programs ...